Business
PDS Announces Trial of its Lead Product, PDS0101
PDS Announces Trial of its Lead Product, PDS0101.
About this update from Emv Capital Plc
[{"type":"text","content":"\n \n \n RNS Number : 1063P\n NetScientific PLC\n 05 June 2020\n \n \n \n \n NetScientific plc\n \n \n (\"NetScientific\" or the \"Company\")\n \n \n PDS Biotech Announces Clinical Trial of Its Lead Immunotherapy Product, PDS0101, in Combination with Chemoradiotherapy in Advanced Cervical Cancer\n \n \n NetScientific plc (AIM:NSCI), the transatlantic healthcare IP commercialisation group, announces that its portfolio company PDS Biotechnology Corporation (\"PDS\") (Nasdaq: PDSB) announced yesterday a Phase 2 clinical trial to evaluate its lead immunotherapy product, PDS0101, in combination with standard of care chemoradiotherapy for treatment of locally advanced cervical cancer.\n \n \n NetScientific holds 7.18% of PDS' undiluted share capital.\n \n \n The full details of the announcement are set out below and can be found here: \n \n https://www.pdsbiotech.com/investors/news-center/press-releases/press-releases1/56-2020-news/393-iotechnnounceslinicalrialoftseadmmunother20200604\n \n \n \n # # #\n \n \n PDS Biotech Announces Clinical Trial of Its Lead Immunotherapy Product, PDS0101, in Combination with Chemoradiotherapy in Advanced Cervical Cancer\n \n \n FLORHAM PARK, N.J., June 04, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company's proprietary Versamune® T-cell activating technology, today announced a Phase 2 clinical trial to evaluate its lead immunotherapy product, PDS0101, in combination with standard of care chemoradiotherapy for treatment of locally advanced cervical cancer.\n \n \n The clinical trial will be conducted at The University of Texas MD Anderson Cancer Center and the Lyndon B. Johnson Hospital in Houston by Ann H. Klopp, M.D., Ph.D., Associate Professor of Radiation Oncology and Olsi Gjyshi, M.D., Ph.D. The clinical trial will investigate the safety and anti-tumor efficacy of the PDS0101-chemoradiation combination, and their correlation with critical biomarkers of an immune response in patients with locally advanced cervical cancer. \n \n \n On September 19, 2019, PDS Biotech announced the results of a PDS0101 Phase 1 clinical study in cervical neoplasia (pre-cervical cancer) patients. PDS0101 is being developed to treat multiple cancers asso...